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Abstract 29	  
	   2	  
Tissue transglutaminase (TG2) is a multifunctional protein cross-linking enzyme that 1	  
has been implicated in apoptotic cell clearance but is also important in many other 2	  
cell functions including cell adhesion, migration and monocyte to macrophage 3	  
differentiation. Cell surface-associated TG2 regulates cell adhesion and migration, 4	  
via its association with receptors such as syndecan-4 and β1 and β3 integrins.  5	  
Whilst defective apoptotic cell clearance has been described in TG2-deficient mice, 6	  
the precise role of TG2 in apoptotic cell clearance remains ill-defined. Our work 7	  
addresses the role of macrophage extracellular TG2 in apoptotic cell corpse 8	  
clearance. Here we reveal TG2 expression and activity (cytosolic and cell surface) in 9	  
human macrophages and demonstrate that inhibitors of protein crosslinking activity 10	  
reduce macrophage clearance of dying cells. We show also that cell-impermeable 11	  
TG2 inhibitors significantly inhibit the ability of macrophages to migrate and clear 12	  
apoptotic cells through reduced macrophage recruitment to, and binding of, apoptotic 13	  
cells. Association studies reveal TG2-syndecan-4 interaction through heparan 14	  
sulphate side chains, and knockdown of syndecan-4 reduces cell surface TG2 15	  
activity and apoptotic cell clearance. Furthermore, inhibition of TG2 activity reduces 16	  
crosslinking of CD44, reported to augment AC clearance. Thus our data define a role 17	  
for TG2 activity at the surface of human macrophages in multiple stages of AC 18	  
clearance and we propose TG2, in association with heparan sulphates, may exert its 19	  
effect on AC clearance via a mechanism involving the crosslinking of CD44.  20	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Introduction 1	  
Transglutaminases are a family of enzymes that catalyse covalent bond formation 2	  
between lysine and glutamine-residues in target proteins leading to their 3	  
posttranslational modification1. TG2 is the most widely expressed family member2 4	  
and is found both in the cytoplasm and extracellularly at the cell surface3. When 5	  
externalized, TG2 is found associated with integrins4 and heparan sulphates (HS)5-8. 6	  
Following translocation to the cell surface, it is deposited into the extracellular 7	  
matrix3. Whilst protein cross-linking is the most studied function of TG2, it also 8	  
participates in other biological processes unrelated to its transamidase activity9- e.g. 9	  
cell adhesion through cell surface association with integrins4 and syndecans5, 6, 8, 10, 10	  
11. However recent work has shown that the extracellular crosslinking activity of TG2 11	  
is involved in S100A4-related cell migration involving a syndecan-4 and β1 integrin 12	  
co-signalling pathway12.  13	  
 14	  
Unwanted cells within the body are removed by apoptosis, a process which 15	  
culminates in apoptotic cell (AC) removal by professional phagocytes (macrophages) 16	  
and accompanying anti-inflammatory responses to prevent inflammatory and 17	  
autoimmune conditions13. Removal of AC is an integrated, multistep process that in 18	  
vivo involves recruitment of macrophages. This is followed by recognition and 19	  
binding of cell corpses prior to engulfment (phagocytosis) through the use of a range 20	  
of receptors and soluble bridging molecules to bind dying cell ligands14-17. Tissue 21	  
transglutaminase (TG2) has been shown to play an important role in this process.   22	  
 23	  
Important previous work utilised TG2-/- mice to reveal defective clearance of AC and 24	  
reduced TGF-β1 with strong association with inflammation and autoimmunity18.  25	  
Further detailed study defined a role for cell surface TG2 in engulfment of AC 26	  
through phagocytic portal stabilisation19.  In this context TG2 was shown to function 27	  
through the interaction with β3 integrin and the AC opsonin MFG-E8. Despite this 28	  
significant previous work, the molecular associations and function of TG2 at the 29	  
surface of human macrophages has not been fully defined. 30	  
 31	  
The aim of this study was to characterise TG2 in the context of human 32	  
macrophages. Using a panel of TG2 inhibitors, including both known cell-permeable 33	  
	   4	  
and cell impermeable inhibitors, TG2 targeted siRNA and an inhibitory antibody; we 1	  
reveal a role of TG2 in the different phases of AC clearance (phagocyte recruitment 2	  
and AC tethering) and also define the cellular site of action of TG2. Furthermore we 3	  
demonstrate for the first time the importance of syndecan-4 in the macrophage cell 4	  
surface localisation of TG2 which is required for efficient clearance of apoptotic cells. 5	  
Recent studies have highlighted a role for cross-linked macrophage CD44 in 6	  
augmenting AC clearance20. Here we further address the involvement of TG2 in 7	  
interacting with CD44 to promote AC clearance. 8	  
9	  
	   5	  
Materials and Methods 1	  
General Reagents 2	  
The general reagents were purchased from Sigma-Aldrich (Poole, UK), unless stated 3	  
otherwise. Purified guinea pig liver transglutaminase (gplTG), biotinylated-4	  
cadaverine (BTC) and the cell permeable TG2 inhibitor Z-DON (Z-DON-Val-Pro-Leu-5	  
OMe) were purchased from Zedira (Darmstadt, Germany). The monoclonal TG2 6	  
activity-blocking antibody D11D12 (GB patent filing 1209096.5) was a kind gift of Dr. 7	  
Tim Johnson (Sheffield University, UK). The TG2 inhibitor 1, 3-dimethyl-2-8	  
imidazolium derivative R28321 and the peptidic TG2 inhibitors R294 and R281 were 9	  
synthesized at Aston University22,23 .  Inhibitor R281 is a membrane-impermeable, 10	  
irreversible TG2 inhibitor22, 23. R294 shows greater specificity for TG2 over other TG 11	  
family members24 and is more water-soluble than R281 and thus is considered to be 12	  
similarly membrane impermeable22.  Cell permeability of R283 has not been formally 13	  
demonstrated and Z-DON is reported to be cell permeable (Zedira). R281, R283 and 14	  
R294 were used at 500µM unless otherwise stated.  Monodansylcadaverine (MDC) 15	  
was used at 100µM. 16	  
The commercial antibodies used in this study are listed in Supplementary Table 1. 17	  
All blots were undertaken using the indicated mouse monoclonal antibodies.  18	  
Immunofluorescence studies utilised either mouse monoclonal or rabbit polyclonal 19	  
antibodies as indicated. 20	  
Cell lines, Cell isolation and culture 21	  
THP-1 (human myelomonocytic cell lines; ATCC) and Mutu I BL25 were cultured in 22	  
RPMI-1640 medium (PAA, Yeovil, UK) containing 2mM L-glutamine supplemented 23	  
with 10% FCS (PAA, Yeovil, UK) and 100IU/ml penicillin and 100µg/ml streptomycin. 24	  
Cells were cultured at 37°C in a humidified environment at 5% CO2. 25	  
Primary blood mononuclear cells were isolated from citrated blood of healthy 26	  
volunteers, following informed consent, by dextran sedimentation and Percoll 27	  
fractionation26. Monocytes were allowed to adhere to tissue culture wells (24 well 28	  
plates) for 1 hour prior to removal of other cells by washing with serum-free RPMI.  29	  
Isolated monocytes were cultured for 7-8 days in macrophage-SFM medium 30	  
(Invitrogen Corp., Paisley, UK) at 37°C in 5% CO2 incubator 27. 31	  
	   6	  
THP-1 differentiation to macrophage-like cells 1	  
Differentiation of THP-1 into macrophage-like cells was induced by treating THP-1 2	  
cells with 250nM phorbol ester (PMA; Sigma, UK), 100nM dihydroxyvitamin D3 3	  
(VD3; Enzo Life Sciences, UK) or both (DS:double-stimulated) for 48-72h at 37°C in 4	  
5% CO2 incubator in growth medium.  Differentiation was confirmed by light 5	  
microscopy28. 6	  
Apoptosis induction and quantification 7	  
Mutu l (Burkitt’s lymphoma cells) were exposed to 100mJ/cm2 UV-B irradiation, using 8	  
a Chromata-vue C71 light box and UVX radiometer (UV-P Inc., Upland, CA, USA) 9	  
and incubated for 16h to allow apoptosis to proceed29. For analysis of apoptotic 10	  
nuclear morphology, cells were fixed in 1% (w/v) formaldehyde in PBS, stained with 11	  
4,6-diamidino-2-phenylinole (DAPI, Sigma, 250ng/ml in PBS) for 5 min and observed 12	  
using inverted epifluorescence microscopy. For quantitative analyses, cells stained 13	  
for 5 min with acridine orange (Sigma, 10µg/ml in PBS) were enumerated as a 14	  
percentage of apoptotic cells per total number of cells counted per sample using 15	  
Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss Ltd, Welwyn Garden City, 16	  
UK) and Hamamatsu Orca camera driven by Volocity (Perkin-Elmer, UK).  17	  
Annexin V labelling and flow cytometry 18	  
UV irradiated Mutu BL were stained with annexin V-FITC (eBiosciences Ltd, UK). 19	  
Briefly, cells were washed once by centrifugation (200xg, 5 min) and resuspended in 20	  
binding buffer (10mM HEPES pH 7.4, 150mM NaCl, 2.5mM CaCl2) containing 21	  
annexin V-FITC (1µl per 2x105 cells) for 15min on ice. Following washing once with 22	  
binding buffer, cells were resuspended in 1ml binding buffer containing propidium 23	  
iodide at a final concentration of 20µg/ml. Samples were analysed immediately on a 24	  
Quanta SC flow cytometer (Beckman Coulter, High Wycombe, UK). A minimum of 25	  
5000 events was collected. 26	  
Assays of Phagocyte interaction with apoptotic cells  27	  
Interaction (defined as tethering plus phagocytosis) of apoptotic Mutu by phagocytes 28	  
(THP-1 derived macrophages, HMDMØ) was carried out in 24-well plates30. Briefly, 29	  
phagocytes and AC at a ratio of 1:100 were co-cultured for 1h at 37°C (for 30	  
	   7	  
interaction) or 20°C (for tethering alone) in RPMI containing 0.2% (w/v) bovine serum 1	  
albumin (Sigma). In assays using inhibitors (e.g. TG2 inhibitors, P1 peptide), 2	  
macrophages were treated with appropriate concentrations of inhibitors in serum-3	  
free RPMI for 1h before and throughout the co-culturing with apoptotic cells (2h 4	  
total). Unbound apoptotic cells were removed by extensive washing with PBS and 5	  
cells fixed with 1% (w/v) formaldehyde in PBS. Cells were stained with DiffQuick II 6	  
(Medion Diagnostics GmbH, Switzerland) for 2 min, the stain replaced with PBS and 7	  
cells scored by light microscopy for the percentage of macrophages interacting with 8	  
apoptotic cells. At least 200 macrophages were scored in each of triplicate wells per 9	  
experiment and at least three independent replicates were undertaken. For the 10	  
assay of only tethering of AC to macrophages (i.e. excluding phagocytosis), co-11	  
culturing was carried at room temperature (20°C), a temperature non-permissive for 12	  
phagocytosis 29. 13	  
Western blotting 14	  
Cells were washed with ice-cold PBS, pH 7.4 and lysed with cell lysis buffer (50mM 15	  
Tris-HCl, pH 7.4, containing 1% (v/v) Nonidet, 0.5% (w/v) sodium deoxycholate, 16	  
0.1% (w/v) SDS, 1mM benzamidine, 1mM NaF, 1mM Na3VO4, 0.1mM 17	  
phenylmethylsulphonyl fluoride (PMSF) and 1% (v/v) protein inhibitor cocktail 18	  
(Sigma)). Protein quantity in samples was estimated by the DCTM-protein assay 19	  
(detergent-compatible, Biorad). Following protein quantification, lysates containing 20	  
50µg of protein were dissolved with an equal volume of 2X Laemmli buffer (Sigma), 21	  
heated to 95oC for 5min and resolved by standard SDS-polyacrylamide gel 22	  
electrophoresis. Following electro-blotting to nitrocellulose (0.45µm; GE Healthcare, 23	  
UK), membranes were blocked with 5% w/v non-fat milk in TBS-Tween (50mM Tris, 24	  
150mM NaCl, 0.05% v/v Tween 20; pH 7.4) and probed using specific primary 25	  
mouse monoclonal antibodies (1:1000 dilution; Table 1). Anti-mouse secondary 26	  
antibody (1:2000 dilution; GE Healthcare) conjugated with horseradish peroxidise 27	  
(HRP) was used to detect primary antibodies. Detection was carried out by using 28	  
ECL chemiluminescence (GE Healthcare, UK). Equal loading was verified by using 29	  
mouse anti-α-tubulin/β-actin antibodies (1:2000 dilution) and normalisation 30	  
undertaken using densitometry where appropriate. 31	  
Heparinase-treatment of cell surface proteins 32	  
	   8	  
Heparan sulphate side chains were removed from the surface of cells by treatment 1	  
of cells with heparinase II or, as a control, chondroitinase. Briefly, THP-1-derived 2	  
macrophages were treated with heparinase II (5 units/ml) or chondroitinase (5 3	  
units/ml) in serum-free RPMI (1h, 37°C).  Following incubation cells were washed 4	  
three times with complete culture medium (RPMI supplemented with serum) prior to 5	  
use in further experiments (e.g. assays of macrophage function for AC interaction). 6	  
Isolation of cell surface proteins using biotinylation  7	  
Biotinylation of cell surface proteins was carried out, to permit purification and 8	  
assessment of cell surface proteins in isolation from other cell components, as 9	  
described previously6. Briefly, cells were rinsed with ice-cold PBS (pH 8.0) and were 10	  
labelled with 0.8µM sulfo-NHS-LC-biotin (Pierce) dissolved in PBS (pH 8.0) at 4°C 11	  
for 20 min. Following washing with 50mM Tris–HCl (pH 8.0) cells were lysed in 1% 12	  
(w/v) SDS in PBS with benzonase (1:1000 of 250U/µl) for 30 min on ice. Cell lysates 13	  
containing 600µg of protein, following centrifugation at 13,000 xg for 20 min to 14	  
remove non-broken cells, were added to 50µl Neutr-Avidin-Agarose resin beads 15	  
(Pierce) which were initially washed with PBS supplemented with 1% (w/v) BSA and 16	  
incubated at 4°C overnight on a rotating platform. After washing with PBS, resin 17	  
beads bound biotin-labelled cell surface proteins were extracted by boiling with 2X 18	  
Laemmli buffer and analysed by western blotting. A non-biotinylated cell sample was 19	  
also run to ensure that the pulldown was specific only for cell surface biotinylated 20	  
TG2 (supplementary figure 1A).  21	  
Co-immunoprecipitation to study protein association  22	  
Co-immunoprecipitation to detect interaction between proteins was carried out as 23	  
described previously11. Briefly, cell lysates (equivalent of 150µg of protein) were pre-24	  
cleared by the addition of 50µl of washed protein-G-Sepharose beads (GE 25	  
Healthcare) for 1 hour prior to bead removal by centrifugation (13000xg, 10 min). 26	  
Approximately 0.5µg of appropriate mouse monoclonal antibody was added to pre-27	  
cleared cell lysates and incubated for 90min at 4oC on a rocking platform to form 28	  
immunocomplexes with respective protein of interest. Immunocomplexes were pulled 29	  
down by incubating with protein-G-Sepharose beads (50µl), the beads washed in 30	  
PBS three times prior to harvest by centrifugation.  Immunocomplexes were 31	  
subsequently collected via boiling in 30µl of 2x Laemmli buffer. Immunocomplexes 32	  
	   9	  
with an isotype control antibody (mouse IgG1/kappa: MoPC21) were also pulled 1	  
down as a known negative control to exclude the possibility that the protein of 2	  
interest is binding non-specifically to beads or antibody. Immunoprecipitated proteins 3	  
were separated using SDS-PAGE and detected via western blotting by using specific 4	  
antibodies. 5	  
Assessment of cell surface TG2 activity via biotin cadaverine incorporation 6	  
Measurement of TG2 activity via biotin cadaverine incorporation into fibronectin was 7	  
carried as described previously5, 11 with minor modifications. Briefly, a 96-well plate 8	  
was coated with 5 µg/ml of fibronectin in wash buffer (50mM Tris-HCl, pH 7.4) 9	  
overnight at 4°C. After rinsing wells with 50mM Tris-HCl (pH 7.4) and blocking with 10	  
3% (w/v) BSA in 50mM Tris-HCl, pH 7.4 (30min, 37°C), cells were seeded into the 11	  
wells at 2x104 per well in serum-free RPMI medium containing 0.132mM biotin-12	  
cadaverine. Wells with 100ng of gplTG with 10mM Ca2+ or 10mM EDTA are used as 13	  
positive and negative controls, respectively. Following incubation for 2h at 37°C (in 14	  
the presence of inhibitors as appropriate to the individual experiment), the reaction 15	  
was terminated by addition of 2mM EDTA in PBS, pH 7.4 and the cells were 16	  
removed by 0.1% (w/v) deoxycholate in 2mM EDTA in PBS, pH 7.4. After rinsing 17	  
wells with wash buffer and blocking with 3% (w/v) BSA in 50mM Tris-HCl, pH 7.4 for 18	  
30min at 37°C, biotin-cadaverine incorporated into fibronectin was detected by 19	  
incubating at 37°C for 1h with blocking buffer conjugated with HRP-conjugated Extr-20	  
avidin (1:1000; Sigma-Aldrich, UK). HRP was detected using OPD (Sigma) and 21	  
colour development was terminated by addition of 50µl of 2.5M H2SO4. The 22	  
absorbance was measured 492nm.  23	  
Similarly, biotin cadaverine incorporation into TG2-CD44 cross-linking was also 24	  
carried out, where 1X105 THP-1/DS MØ were pre-incubated with 8µM biotin-25	  
cadaverine in the presence or absence of non cell-permeable TG2 inhibitor R281 in 26	  
serum-free RPMI medium at 37°C for 2h.	   Where R281 was used, MØ were pre-27	  
treated with inhibitor for 1h prior to the addition of BTC. Following BTC incorporation, 28	  
cell lysates equivalent to 150µg protein were subject to pull down of biotin-containing 29	  
molecules by Neutr-Avidin-Agarose resin beads. The pull downs were probed by 30	  
western blotting for CD44 to reveal TG2-mediated BTC incorporation into CD44.  31	  
 32	  
	   10	  
Chemotaxis and migration studies 1	  
 2	  
MØ chemotaxis towards AC was studied using a Dunn chemotaxis chamber 3	  
(Hawksley, Sussex) in conjugation with time-lapse microscopy31. This horizontal 4	  
migration chamber establishes a true gradient of attractant rather than the ‘step 5	  
gradient’ associated with use of vertical transwell-based systems.  THP-1/DS cells, 6	  
treated as appropriate with cell-impermeable TG2 inhibitor R281 (1h in serum-free 7	  
RPMI medium), were detached into 5mM EDTA in PBS at 37oC and reseeded to 8	  
plastic cover slips. Following incubation at 37oC for 20min in RPMI, the coverslip was 9	  
inverted on a chemotaxis chamber and sealed in position using wax with 10	  
chemoattractants in the outer well.  Cell migration was recorded using time-lapse 11	  
microscopy (Zeiss Axiovert 200M controlled by Improvision Volocity software).  12	  
Quantitative assessment of collected sequential images to allow mapping of 13	  
individual cells was carried out using Image J and the Ibidi Chemotaxis and 14	  
Migration tool (version 2.0, Ibidi), which provides measures of distance migrated 15	  
(Euclidian) and directness.   16	  
Immunofluorescence staining 17	  
To detect cell surface proteins by indirect immunofluorescence, cells at 5x104 per 18	  
well on multi-well glass slides (Hendley, Essex, UK) were blocked with 3% (w/v) BSA 19	  
in PBS (pH 7.4) for 30min on ice. Following washes with PBS, cells were incubated 20	  
with primary mouse monoclonal antibodies (1:100 dilution) or rabbit polyclonal 21	  
antibodies (1:100 dilution), in serum-free RPMI for 2h on ice. Cell washing with PBS, 22	  
pH 7.4 was followed by incubation with specific secondary antibody reagents (anti-23	  
mouse or anti-rabbit as appropriate) conjugated with either FITC or PE (1:100 24	  
dilution) for 2h on ice. Stained cells were washed twice with PBS, fixed with 1% w/v 25	  
formaldehyde in PBS and mounted with Vectashield containing DAPI (Vector 26	  
Laboratories).  Cells were examined using confocal microscopy (Leica 27	  
Microsystems). 28	  
siRNA silencing of individual cellular components 29	  
Four different siRNAs targeting human syndecan-4 and another four different 30	  
siRNAs targeting TG2 were used to inhibit/knockdown the expression of both the 31	  
proteins, while the non-silencing control siRNA was used as the negative control. All 32	  
siRNA were supplied at 10µM (Qiagen).  Transfection was carried out according to 33	  
	   11	  
manufacturer’s protocol with slight modifications. Briefly, 5x105 THP-1 cells were 1	  
seeded (1.5ml) to 6-well plates and were stimulated with PMA and VD3 to 2	  
differentiate to macrophage-like cells. Following 24h of differentiation, cells were 3	  
transfected by the dropwise addition of 100µl of transfection mix (1µl siRNA, 9µl 4	  
HiPerfect transfection reagent (Qiagen), 90µl serum-free RPMI). Following 48h of 5	  
incubation with the siRNA, whole cell lysates were used to analyse the level of 6	  
protein expression by western blotting. Additionally cells at this same time point were 7	  
used for additional functional studies as appropropriate. 8	  
Statistical Analysis 9	  
Data are expressed as the mean ± S.E. for at least three independent replicate 10	  
experiments (n ≥3).  Statistical tests were undertaken using InStat (GraphPad, La 11	  
Jolla, CA, USA). Statistical analysis of results was undertaken using one-way 12	  
analysis of variance (ANOVA) using a post-test depending on the requirement. 13	  
14	  
	   12	  
Results  1	  
TG2 inhibitors reduce MØ-AC interaction through actions on macrophages  2	  
Initial studies sought to address whether THP-1 cells, stimulated to differentiate to 3	  
MØ, express TG2 as this cell model provides a valuable tool for undertaking many 4	  
experiments in a controllable system. Thus we undertook western blot analysis for 5	  
TG2 on cell lysates of THP-1 cells (stimulated with dihydroxyvitamin D3, PMA or 6	  
PMA/VD3) and analysed for the presence of MØ cell surface TG2 following cell 7	  
surface biotinylation, We show stimulated THP-1 cells (PMA or PMA/VD3) express 8	  
TG2 strongly and this expression includes cell surface expression (Figure 1A and 9	  
Supplementary Figure 1A). Cell surface expression was also clearly revealed with 10	  
immunofluorescence microscopy (Figure 1A) in PMA and PMA/VD3 cells but not in 11	  
THP-1 cells or VD3 cells. The lack of detectable cell surface TG2 in THP-1 cells or 12	  
those stimulated solely with VD3 is consistent with the lack of TG2 expression noted 13	  
in whole cell lysates. 14	  
 15	  
To confirm a role for TG2 in human MØ clearance of AC, THP-1 MØ (THP-1/PMA, 16	  
THP-1/VD3 and THP-1/DS) were treated initially with TG2 inhibitors R283 & Z-DON 17	  
(the latter is claimed to be cell permeable by the manufacturer Zedira) or R281 and 18	  
R294 (R281 is cell-impermeable22, 23 and R294 more water soluble and likely 19	  
therefore to be similarly cell-impermeable22), irreversible TG2 site-directed inhibitors 20	  
at a concentration of 500µM22. Following a 1h inhibitor treatment, macrophages were 21	  
assessed for their ability to interact with apoptotic B cells, where interaction is 22	  
defined as the sum of both tethering (binding) and phagocytosis (engulfment) of AC. 23	  
All four TG2 inhibitors including the cell-impermeable inhibitors 281 and 294 reduced 24	  
significantly MØ-AC interaction in those MØ that expressed TG2 (THP-1/PMA, THP-25	  
1/DS; Supplementary Figure 2A), suggesting that TG2 is mediating its actions at the 26	  
cell surface. Further studies revealed the inhibitor effects to be dose dependent 27	  
(Figure 2B and Supplementary Figure 2B) with no cellular toxicity (Supplementary 28	  
Figure 3). AC clearance by phagocytes is a multistage process and to assess the 29	  
role of TG2 in the tethering of AC to MØ, TG2 inhibitors were added to MØ-AC co-30	  
cultures at 20oC, a temperature non-permissive for phagocytosis29. Inhibition of cell 31	  
tethering was shown by all the TG2 inhibitors tested (Figure 1C). Similarly, the 32	  
	   13	  
inhibitors reduced AC interaction with primary human monocyte-derived 1	  
macrophages (Figure 1D). 2	  
In order to identify the cellular target of TG2 inhibition MØ or AC were individually 3	  
treated with TG2 inhibitors prior to co-culture. Treatment of MØ led to the most 4	  
profound reduction in MØ-AC interaction (Figure 1E), suggesting that the principal 5	  
TG2 inhibition effect is on the MØ not the AC, and that MØ TG2 is required for MØ-6	  
AC interaction. This is further supported by TG2 expression studies (Supplementary 7	  
Figure 3) since in leucocyte cells used as apoptotic targets, TG2 was not detectable 8	  
by western blot. These data support a prominent role for TG2 in MØ-AC interaction 9	  
in those highly differentiated human MØ cells (HMDMØ, THP-1/PMA, THP-1/DS) but 10	  
not in the monocyte-like models (THP-1 and THP-1/VD3). 11	  
TG2 inhibitors reduce MØ migration towards AC-derived microparticles  12	  
Macrophage migration to dying cells is an important event in vivo for phagocytic 13	  
removal of AC and MØ have been shown to migrate towards AC along a gradient of 14	  
AC-derived microparticles29. To determine the role of TG2 on MØ migration to AC, 15	  
THP-1 cells double-stimulated with PMA/VD3 (DS) were assessed for their migration 16	  
towards AC microparticles in the presence or absence of the TG2 cell-impermeable 17	  
inhibitor R281. Inhibition of TG2 resulted in a dramatic loss of MØ migration towards 18	  
AC (Figure 2A), with a parallel effect on MØ directionality (Figure 2A). Direct 19	  
(Euclidean) distance migrated between start and end points and velocity of migration 20	  
had reduced significantly with TG2 inhibitor treatment (Figure 2B). 21	  
 22	  
TG2 knockdown in MØ showed limited ability to interact with AC 23	  
To further confirm a role for TG2 in MØ-AC interaction, THP-1 cells were transfected 24	  
with four different siRNA targeting human TG2, while the global non-silencing (NS) 25	  
siRNA was used as the control. After stimulating THP-1 with PMA and VD3 for 24h, 26	  
cells were transfected with siRNA for a further 48h before whole cell lysates were 27	  
analysed by western blotting for TG2 expression (Figure 3A). TG2 siRNA1 caused a 28	  
reduction (approximately 70%) in TG2 expression, in comparison to NS siRNA, and 29	  
this TG2 knockdown reduced interaction between siRNA1-treated macrophages and 30	  
AC by around 50% when compared to the inactive control siRNA transfected cells 31	  
(Figure 3B). Importantly, the reduced MØ-AC interaction noted with either the cell-32	  
	   14	  
impermeable TG2 inhibitor (R281) or siRNA knockdown of TG2, acting either 1	  
independently or in combination, could be partially rescued by the addition of 2	  
exogenous active TG2 (Figure 3C) indicating the specificity of action of the TG2 3	  
effects shown here and confirming that active TG2 at the MØ cell surface is 4	  
important for apoptotic cell clearance. 5	  
Cell surface TG2 protein cross-linking activity mediates MØ-AC interaction  6	  
Site-directed TG2 irreversible inhibitors can block both the transamidating activity 7	  
and alter TG2 conformation by holding it in its open conformation after reaction32. 8	  
Such changes to TG2 conformation could affect binding of TG2 to its high affinity 9	  
ligands such as heparan sulphates6. To address the involvement of TG2 activity 10	  
and/or conformation in MØ-AC interactions, the use of the competitive primary amine 11	  
substrate monodansylcadaverine (MDC) at a concentration of 100µM, which also 12	  
blocks protein cross-linking was used. MDC reduced MØ-AC interaction to the same 13	  
degree as the irreversible cell-impermeable inhibitor R281; suggesting alterations to 14	  
TG2 activity, not conformation were responsible for altered AC clearance (Figure 15	  
4A).                                                                                                                                                                                                           16	  
Given that our results suggest the activity of cell surface TG2 is important in AC 17	  
clearance, we next demonstrated the presence of in situ cell surface TG2 activity in 18	  
live cells (Figure 4B) using established techniques5, 11. This activity was inhibited 19	  
using our panel of TG-2 inhibitors.  Add-back of purified exogenous active TG2 to the 20	  
inhibitor treated MØ resulted in partial rescue of TG2 activity (Figure 4B). Primary 21	  
human MØ showed a similar pattern of cell surface TG2 activity (Supplementary 22	  
Figure 5). Additionally, TG2 knockdown by siRNA resulted in loss of cell surface TG2 23	  
activity (Figure 4C) consistent with reduced TG2 expression (Figure 3A). 24	  
Furthermore, a specifically targeted TG2 activity-blocking antibody33 inhibited MØ-25	  
AC interaction in a dose-dependent manner (Figure 4D). Taken together these data 26	  
demonstrate an important role for TG2 cross-linking activity at the surface of human 27	  
MØ in mediating AC removal. 28	  
TG2 associates with Syndecan-4  29	  
We next investigated the involvement of TG2 binding partners at the human MØ cell 30	  
surface. In other cells, TG2 has been shown to have a strong binding affinity for 31	  
	   15	  
heparan sulphates (HS) of the cell surface receptor syndecan-4 that is important in 1	  
the translocation of TG2 to the cell surface and extracellular matrix (ECM)5, 11.  Thus 2	  
an attractive candidate partner was syndecan-4, a heparan sulphate proteoglycan 3	  
(HSPG) that acts as a receptor for TG2 via its HS chains thus mediating an RGD-4	  
independent cell adhesion via a TG2-FN complex6. Through the use of western 5	  
blotting and immunofluorescence staining (Figure 5A) we demonstrate clear 6	  
expression of syndecan-4 in THP-1/DS cells that also show strong TG2 expression. 7	  
To confirm a possible interaction between cell surface TG2 and syndecan-4, we 8	  
performed co-immunoprecipitation assays and demonstrate TG2-syndecan-4 9	  
interaction in MØ cells (Figure 5B and Supplementary Figure 1B). 10	  
Loss of cell surface heparan sulphates or syndecan-4 reduces cell surface 11	  
TG2 expression and activity resulting in reduced MØ-AC interaction 12	  
HS on HSPGs (e.g. syndecan-4) mediate TG2 binding at cell surfaces5, 11. In order to 13	  
test the importance of HS and syndecan-4 in presenting TG2 at the human 14	  
macrophage cell surface where it mediates AC clearance, we studied the effect of 15	  
HS removal, syndecan-4 knockdown and blocking TG2-syndecan-4 binding on MØ-16	  
AC interaction. Loss of HS, via heparinase II treatment, resulted in loss of cell 17	  
surface TG2 activity (Figure 6A) and reduced MØ-AC interaction (Figure 6B). Using 18	  
syndecan-4 specific siRNAs, a maximal reduction in SDC4 expression 19	  
(approximately 60%) was obtained (Supplementary Figure 6A) resulting in reduced 20	  
presence (Figure 6C) and activity (Figure 6D) of cell surface TG2 though this was 21	  
only evident with the most robust knockdown of SDC4 provided by siRNA construct 22	  
2. This strongly suggests that cell surface TG2 is anchored, at least in part, to 23	  
syndecan-4, the loss of which results in loss of cell surface TG2 activity. No loss of 24	  
syndecan-4 expression is found in TG2 knockdown THP-1/DS (Supplementary 25	  
Figure 6B) and total TG2 expression was unaffected by loss of syndecan-4 26	  
expression. 27	  
Syndecan-4 knockdown reduces MØ-AC interaction and when syndecan-4 28	  
knockdown THP-1/DS cells were also treated with R281, no further reduction in MØ-29	  
AC interaction occurs (Figure 6E) suggesting no additive effect and supporting the 30	  
notion that the involvement of syndecan-4 or TG2 in AC clearance are functionally 31	  
	   16	  
related. These data confirm HS as prime receptors for TG2 binding on the MØ cell 1	  
surface and syndecan-4 as one HSPG important for TG2 binding. 2	  
To further strengthen our understanding of TG2-syndecan-4 binding via HS, we used 3	  
the P1 peptide (200NPKFLKNAGRDCSRRSS216), which mimics the heparin binding 4	  
domain within TG2 and competes for its binding to syndecan-48. Cells were treated 5	  
with P1 peptide or a scrambled control P1 peptide for 30min and here we 6	  
demonstrate that P1 peptide (but not the scrambled control peptide) reduces MØ-AC 7	  
interaction (Figure 6F) in a dose-dependent manner (supplementary Figure 6C). 8	  
However, upon exogenous addition of active TG2, the loss of MØ-AC interaction was 9	  
found to be partially compensated (Figure 6F), suggesting that TG-2 bound to 10	  
syndecan-4 via HS is crucial in mediating MØ-AC interaction. 11	  
TG2 interacts with CD44 at MØ cell surface: A possible TG2 mediated CD44 12	  
cross-linking.   13	  
CD44, an HSPG and established receptor for hyaluronan, is important in immune 14	  
cells’ proliferation and differentiation, cell adhesion, migration, and inflammation34-36. 15	  
CD44 undergoes complex alternative mRNA splicing and posttranslational 16	  
modifications resulting in a family of isoforms with distinct biological functions37. 17	  
CD44 is a known phagocytic receptor38 that, when cross-linked by antibody, 18	  
augments AC clearance20. We therefore investigated whether TG2 may mediate 19	  
CD44 crosslinking to facilitate AC clearance. 20	  
 21	  
Initially we examined CD44 expression and found it paralleled TG2 expression 22	  
(Figure 7A) in THP-1/DS, THP-1/PMA and HMDMØ. Interestingly, two major distinct 23	  
molecular weight bands for CD44 were expressed. To address the possibility that the 24	  
high molecular weight CD44 is a TG2 cross-linked form (cross-linked to itself or other 25	  
molecules), CD44 expression in TG2 inhibitor-treated cells was examined. Inhibition 26	  
of TG2 was associated with a loss in the intensity of the high molecular CD44 27	  
(~150kDa) and an increase in the intensity of low molecular weight CD44 (~85kDa) 28	  
consistent with the notion that the high molecular weight CD44 species arises from 29	  
TG2 activity (Figure 7B). Precipitation of TG2 resulted in the co-precipitation of CD44 30	  
(Figure 7C) suggesting a possible TG2-CD44 interaction. Importantly, in support of 31	  
the small molecular CD44 species being a substrate of TG2 following prior treatment 32	  
	   17	  
with the non-cell-permeable inhibitor R281 the presence of the high molecular weight 1	  
CD44 species was barely detectable in primary human macrophages (Figure 7D).  2	  
To further confirm that CD44 is a potential substrate of macrophage cell surface 3	  
TG2, THP-1/DS were incubated with the TG2 primary amine substrate biotin-4	  
cadaverine (BTC). Following cell lysis, proteins with TG2 incorporated BTC were 5	  
affinity purified with Neutr-Avidin-Agarose resin beads. Western blot analysis for 6	  
CD44 revealed both high and low molecular weight bands for CD44 were present 7	  
(Figure 8A). However, treatment with the TG2 irreversible inhibitor R281 prior to BTC 8	  
incorporation resulted in a significant loss in high molecular weight CD44 (Figure 8A) 9	  
confirming that CD44 is a potential substrate for cell surface TG2. Whilst R281 is an 10	  
irreversible inhibitor of TG2, the inhibition is incomplete (figure 4B) and this provides 11	  
an explanation of why there is BTC incorporation remaining even in the presence of 12	  
TG2 inhibitors. The cell surface interaction of TG2 with CD44 was confirmed by 13	  
immunofluorescence analysis of TG2 and CD44 which showed co-localisation of 14	  
CD44 with TG2, although not all TG2 showed co-localisation with CD44 (Figure 8B). 15	  
This provides further evidence that TG2 interacts with CD44 supporting both the co-16	  
immunoprecipitation analysis and BTC incorporation studies.  17	  
 18	  
To study the effect of TG2-CD44 interaction on MØ ability to interaction with AC, 19	  
MØ-AC interaction assay was performed following CD44 knockdown in MØ. CD44 20	  
siRNA-9 caused a significant reduction in CD44 expression in comparison to NS 21	  
siRNA (Supplementary Figure 7A), and loss of CD44 resulted in reduced MØ-AC 22	  
interaction by around 40% when compared to the NS siRNA transfected cells (Figure 23	  
8C). There was no effect on cell surface TG2 expression (Supplementary Figure 7B). 24	  
Interestingly, treating MØ with TG2 inhibitor R281 or treating CD44 siRNA-9 25	  
transfected MØ with R281 showed a further reduction in the MØ-AC interaction, 26	  
suggesting that TG2 can act independently of CD44, possibly through syndecan 4.  27	  
28	  
	   18	  
 1	  
FIGURE 1. TG2 inhibitors reduce apoptotic cell clearance by macrophages.  2	  
(A) Western blot analysis revealing both whole cell lysate (WCL) and cell surface 3	  
(CS) TG2 expression in THP-1 cells-derived MØ (through stimulation with VD3, PMA 4	  
or both (DS)) and primary HMDMØ. THP-1/PMA, THP-1/DS and HMDMØ but not 5	  
undifferentiated THP-1 and THP-1/VD3 showed detectable TG2 expression by 6	  
western blotting (left panel). Cell surface TG2 was detected spefically following cell 7	  
	   19	  
surface protein biotinylation, prior to isoation of biotinylated proteins using Neutr-1	  
avidin as described in the materials and methods. Equal loading was verified by 2	  
probing with mouse anti-tubulin antibody on stripped membranes. Similarly, surface 3	  
expression of TG2 in THP-1/DS was revealed upon indirect immunofluorescence 4	  
staining of live (i.e. unpermeabilised) cells with mouse monoclonal anti-TG2 antibody 5	  
(Cub7402) in conjugation with FITC-congugated anti-mouse secondary antibody 6	  
(right panel). Nuclei were stained with DAPI. The bar corresponds to 25µm. (B) 7	  
Dose-dependent effect of three site-directed irreversible TG2 inhibitors on MØ (THP-8	  
1/DS) interaction with AC. Inhibitors were applied to MØ for 1h prior to and 9	  
throughout the co-culture with AC. ‘Interaction’ is defined as the combination of those 10	  
AC tethered (bound) to the surface of MØ and those internalised (phagocytosed).  11	  
(C) TG2 inhibitors (including cell-impermeable R281 and its more water soluble 12	  
counterpart R294) inhibited MØ (THP-1/DS) tethering of AC (i.e. where only surface 13	  
binding of AC to MØ is assayed without contribution from phagocytic events) and, 14	  
(D) a similar effect of TG2 inhibitors is seen in HMDMØ interacting with AC. (E) 15	  
Treatment of either MØ alone or AC alone with TG2 inhibitors showed significant 16	  
reduction in MØ-AC interaction following inhibitor treatment of MØ. Data shown are 17	  
mean ±S.E. for n≥3 independent replicates. Statistical analysis was conducted using 18	  
ANOVA followed by Bonferroni post-test (*P<0.05; *** P<0.001). 19	  
20	  
	   20	  
 1	  
FIGURE 2. TG2 inhibition reduces macrophage migration to AC 2	  
(A) The effect of TG2 inhibitor R281 on MØ (THP-1/DS) migration towards AC was 3	  
tested using a Dunn chemotaxis chamber coupled with time-lapse imaging phase 4	  
contrast microscopy over 20h. MØ were pre-treated for 1h with the inhibitor prior to 5	  
exposure to AC in a Dunn chamber.  Cell migration was tracked using ImageJ 6	  
software and tracks were analysed using Chemotaxis and Migration tool 2.0 (IBIDI), 7	  
and were plotted as distance migrated (µm). The track of each cell is shown, starting 8	  
at the cross hairs and finishing at a dot, with the position of the attractant at the top 9	  
of each plot. Representative plots are shown. R281, a cell-impermeable TG2 10	  
inhibitor induced a dramatic reduction in MØ migration. A loss of directionality is 11	  
shown in the rose diagram (insets). (B) The distance migrated and the velocity at 12	  
which the cells migrate in the presence and absence of TG2 inhibitor (R281) is 13	  
	   21	  
presented as mean ±S.E. for n≥3 independent replicates. Statistical analysis was 1	  
conducted using ANOVA followed by Bonferroni post-test (**P<0.01; *** P<0.001). 2	  
 3	  
 4	  
FIGURE 3. Addition of exogenous active TG2 can compensate for the impaired 5	  
macrophage-apoptotic cell interaction seen with TG2 knockdown or inhibition  6	  
(A) Western blot analysis of TG2 expression using mouse anti-TG2 in THP-1/DS 7	  
following transfection with the indicated TG2-targeted siRNA constructs or a non-8	  
specific control (NS). A representative blot is shown along with densitometric 9	  
analysis from three independent experiments. Statistics compare to NS control 10	  
construct.  (B) TG2 knockdown with siRNA 1 reduces MØ (THP-1/DS) interaction 11	  
with AC compared to cells similarly transfected with a control siRNA (NS siRNA). (C) 12	  
	   22	  
Reduced MØ-AC interaction as a result of TG2 knock down (siRNA 1) or TG2 1	  
inhibition (R281) is rescued by the addition of exogenous active, but not inactive 2	  
TG2. Where appropriate, inhibitors were applied to MØ for 1h prior to and throughout 3	  
the co-culture with AC. Data shown are mean ±S.E. for n≥3 independent replicates. 4	  
Statistical analysis was conducted using ANOVA followed by Bonferroni post-test 5	  
(*** P<0.001). 6	  
7	  
	   23	  
 1	  
FIGURE 4.  TG2 activity promotes macrophage-apoptotic cell interaction.  2	  
(A) Monodansylcadaverine (MDC: inhibits crosslinking in the presence of Ca2+, as 3	  
used here, without changing the conformation of TG2) reduces MØ (THP-1/DS) 4	  
interaction with AC.  Similar levels of inhibition are noted with irreversible TG2 5	  
inhibitor R281. All inhibitors were applied to MØ for 1h prior to and throughout the 6	  
co-culture with AC. (B) MØ (THP-1/DS) cell surface TG activity was assessed (via 7	  
biotin-cadaverine incorporation into fibronectin) following MØ treatment with the 8	  
indicated TG2 inhibitor and adding active TG2 exogenously following R281 9	  
	   24	  
treatment. The positive control is gplTG. The negative control comprises the addition 1	  
of 10mM EDTA. (C) Cell surface transglutaminase activity was similarly assessed in 2	  
MØ transfected with the TG2-specific siRNA or a non-specific control (NS siRNA). 3	  
(D) TG2 binding antibody (D11D12) inhibits MØ-AC interaction in a dose-dependent 4	  
manner compared to the isotype control mAb MoPC21. Data shown are mean ±S.E. 5	  
for n≥3 independent replicates. Statistical analysis was conducted using ANOVA 6	  
followed by Bonferroni post-test (*** P<0.001). 7	  
8	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 1	  
FIGURE 5. Macrophage cell surface TG2 associates with syndecan-4.  2	  
(A) Western blot analysis (left panel) reveals the expression of syndecan-4 (detected 3	  
with mouse anti-SDC4 mAb) in undifferentiated and a panel of differentiated THP-1 4	  
MØ cells. Stripped membranes were re-probed with mouse anti-α-tubulin antibody as 5	  
a loading control. Similarly, syndecan 4 expression at the cell surface of THP-1/DS 6	  
MØ was detected using indirect immunofluorescence (mAb to syndecan-4; goat anti-7	  
mouse FITC) and confocal imaging. (B) Interaction between TG2 and syndecan-4 in 8	  
THP-1/DS MØ is revealed by co-immunoprecipitation analyses. Syndecan-4 (SDC4) 9	  
was precipitated using an anti-SDC4 antibody. Precipitated material was separated 10	  
by PAGE and co-precipitation of TG2 assessed by anti-TG2 western blotting (using 11	  
mouse anti-TG2 mAb; anti-mouse-HRP). 12	  
13	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 1	  
Figure 6. TG2 associates with syndecan-4 heparan sulphate side chains and 2	  
mediates macrophage-apoptotic cell interaction.  3	  
Cell surface activity of TG2, and MØ-AC interaction was assessed following 4	  
treatment of MØ (THP-1/DS) with heparinase II (HepII) or chondroitinase (Chon) as 5	  
	   27	  
described in the Methods section. (A) TG activity is reduced following treatment with 1	  
heparinase II to remove heparan sulphate chains. (B) Treatment of MØ with 2	  
heparinase II also resulted in significant loss of MØ interaction with AC. (C) Western 3	  
blot analysis of TG2 (whole cell TG2 or cell surface TG2 isolated following cell 4	  
surface biotinylation and Neutr-avidin isolation of cell surface components) in MØ 5	  
(THP/DS) cells transfected with syndecan-4 specific siRNA or a non-specific (NS) 6	  
siRNA.  This reveals a loss of cell surface (but not whole cell) TG2 when syndecan-4 7	  
expression is reduced. (D) Following siRNA-mediated syndecan-4 knockdown in MØ 8	  
(THP/DS) with the indicated siRNA constructs, cell surface TG2 activity was 9	  
assessed and shows a loss of cell surface TG activity. (E) Syndecan-4 knockdown 10	  
with siRNA (construct siRNA 2) in MØ (THP/DS) was undertaken prior to assessing 11	  
MØ-AC interaction. Addition of R281 was also included (for 1h prior to co-culture and 12	  
throughout the co-culture period) to assess additive effects. (F) MØ (THP-1/DS) 13	  
treated with P1 peptide for 1h prior to co-culture and throughout the co-culture period 14	  
(P1; which competes the heparin binding domain within the TG2) but not a 15	  
scrambled P1 peptide (P1s) show reduced interaction with AC, that is rescued when 16	  
200ng purified exogenous TG2 (exoTG2) is added. Data shown are mean ±S.E. for 17	  
n≥3 independent replicates. Statistical analysis was conducted using ANOVA 18	  
followed by Bonferroni post-test (*** P<0.001). 19	  
20	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 1	  
Figure 7. TG2 interacts with CD44.  2	  
(A) Western blot analysis of CD44 in whole cell lysates of THP-1/PMA MØ, THP-3	  
1/DS MØ and HMDMØ reveals two distinct molecular weight bands for CD44. 4	  
	   29	  
Arrowheads indicate high and low molecular weight bands for CD44. Stripped 1	  
membranes were re-probed with mouse anti-β-actin antibody as a loading control. 2	  
(B) MØ (THP/DS) were treated with the indicated TG2 inhibitors for 1h prior to cell 3	  
lysis and western blot analysis for CD44.  Upper panel: A representative blot 4	  
showing significant loss in high molecular CD44 (~150-160kDa) and an increase in 5	  
the intensity of low molecular weight CD44 (~85-95kDa) in comparison to untreated 6	  
MØ. Stripped membranes were re-probed with anti-β-actin antibody as a loading 7	  
control. Lower panel shows the ratio of the high:low molecular weight bands 8	  
assessed by densitometry from three independent experiments (mean±S.E.). Data 9	  
shown were normalised to the signal from MØ alone.  (C) Immunoprecipitation of 10	  
TG2 from membrane lysates of THP-1/DS MØ and primary HMDMØ cells was 11	  
undertaken and probed on western blot for CD44. This reveals interaction between 12	  
TG2 and CD44 proteins. (D) Upper panel: Western blot analysis of CD44 from 13	  
immunoprecipitates of TG2 following inhibition of TG2 with R281 in HMDMØ 14	  
(representative blot); Lower panel shows the ratio of the high:low molecular weight 15	  
bands assessed by densitometry from three independent experiments (mean±S.E.).  16	  
Arrowheads indicate high and low molecular weight bands for CD44.  HC indicates 17	  
heavy chain and LC indicates light chain. Statistical analysis was conducted using 18	  
ANOVA followed by Dunnett’s post-test (* P<0.05; **P<0.01, *** P<0.001). 19	  
 20	  
21	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 1	  
 2	  
Figure 8. CD44 acts as a substrate for TG2 in mediating apoptotic cell 3	  
clearance.  4	  
	   31	  
(A) THP-1/DS MØ were exposed, in the presence or absence of TG2 inhibitor R281, 1	  
to biotin-cadaverine (BTC) as a measure of cell surface TG2 activity. Where R281 2	  
was used, MØ were pre-treated with inhibitor for 1h prior to the addition of BTC.  3	  
Following BTC incorporation, cell lysates of THP-1/DS MØ were subject to pull down 4	  
of biotin-containing molecules by Neutr-Avidin-Agarose resin beads.  The pull downs 5	  
were probed by western blotting for CD44 to reveal TG2-mediated BTC incorporation 6	  
into CD44. This reveals incorporation of biotin-cadaverine into CD44 proteins in TG2 7	  
expressing cells and reduced incorporation upon treatment with non-permeable TG2 8	  
inhibitor R281. Arrowheads indicate high and low molecular weight bands for CD44. 9	  
A significant loss in high molecular CD44 (~150-160kDa) in comparison to untreated 10	  
MØ is shown. (B) Cell surface TG2 (Red) and CD44 (Green) on the MØ cell surface 11	  
were stained by indirect immunofluorescence, incubating live cells with rabbit anti-12	  
TG2 and mouse anti-CD44 primary antibodies. Cells were further stained with 13	  
secondary reagent (anti-rabbit-PE; anti-mouse-FITC).  TG2 co-localizes with CD44 14	  
on the MØ cell surface (MERGE/Yellow). Staining is visualized by confocal 15	  
microscopy. (C) CD44 and/or SDC4 knockdown with siRNA in MØ (THP/DS) was 16	  
undertaken prior to assessing MØ-AC interaction. Addition of R281 was also 17	  
included to assess additive effects. Data shown are mean ±S.E. for n≥3 independent 18	  
replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni 19	  
post-test (*** P<0.001). 20	  
21	  
	   32	  
Discussion 1	  
Phagocytic removal of apoptotic cells involves an array of phagocyte receptors 2	  
which, directly or indirectly via soluble bridging molecules, facilitate recognition and 3	  
binding of AC associated ligands ultimately leading to corpse uptake16, 17.  As evident 4	  
from previous studies using TG2 deficient mice, TG2 plays a prominent role in AC 5	  
engulfment by promoting phagocytic portal formation18,19. It is also crucially important 6	  
in immune modulation to prevent inflammation and autoimmunity18. Here we extend 7	  
those studies to characterise TG2 in AC clearance and address its location and 8	  
function in human macrophages. Using a TG2-inhibitor-based approach, rather than 9	  
TG2-deficient animals, we address TG2 in human cells that have developed in a 10	  
TG2-replete status before specifically inhibiting TG-2 activity or expression. Thus 11	  
taking our results together with those existing, we provide a comprehensive view of 12	  
TG2 function in AC clearance. 13	  
 14	  
Our initial western blot studies addressed whole cell and cell surface TG2 expression 15	  
in a panel of THP-1 cell-derived macrophage models and HMDMØ. These cells 16	  
expressed TG2 at the cell surface39 with the exception of THP-1 parental cells and 17	  
THP-1/VD3 cells where TG2 was not detectable.  Given the monocyte-like (relatively 18	  
immature) morphology of these cells28, these data suggest TG2 expression is linked 19	  
to monocyte/macrophage maturity40, 41. 20	  
  21	  
Building on the important previous work in mice, we assessed TG2 in human MØ 22	  
through the use of irreversible site-directed TG2 inhibitors22 including proven cell-23	  
permeable (Z-DON, Zedira) or cell-impermeable (R281) inhibitors. All inhibitors 24	  
tested strongly reduced MØ-AC interaction (i.e. tethering and phagocytosis 25	  
combined) and tethering (binding alone) by those MØ that expressed TG2. 26	  
Importantly, similar results were noted for primary human MØ. Detection of TG-2 27	  
expression at the MØ surface coupled with the ability of cell-impermeable inhibitors 28	  
and a TG2-specific inactivating antibody to reduce MØ-AC interaction suggests that 29	  
MØ cell surface TG2 plays a prominent role in MØ-AC interaction. To address the 30	  
issue of inhibitor-induced conformational changes of TG2, as an explanation for 31	  
reduced MØ-AC interaction, the competitive TG2-substrate MDC was employed 32	  
since it blocks TG2-induced protein crosslinking in the presence of Ca2+without any 33	  
irreversible change in TG2 conformation32. Again we demonstrated a significant 34	  
	   33	  
reduction in MØ-AC interaction confirming TG2 crosslinking activity as required for 1	  
AC clearance by human macrophages. This conclusion is further supported by our 2	  
use of siRNA to knockdown TG2 that resulted in reduced expression and cell surface 3	  
activity of TG2. Taken together, with the ability of the TG2 activity-blocking antibody 4	  
to reduce MØ-AC interaction, these data demonstrate for the first time that TG2 on 5	  
the surface of human MØ is important in the tethering and removal of apoptotic cells. 6	  
Importantly we show a requirement for TG2 crosslinking activity in this function. In 7	  
addition to TG2, macrophages are known to express Factor XIIIa (another TG family 8	  
members)42, 40.   To rule out the involvement of this enzyme in macrophage–AC 9	  
interactions we used a TG2-specific inactivating mAb. Additionally we used the 10	  
irreversible TG2 inhibitors R294 (that has an IC50 for Factor XIIIa of greater than 11	  
200µM but has a IC50 for TG2 of 8µM) and R281 (which also has an IC50 for 12	  
FactorXIIIa of greater than 100µM but an IC50 for TG2 of 10µM)24.  In addition, we 13	  
also used TG2 targeted siRNA. The use of the inactivating TG2 mAb and the use of 14	  
TG2 targeted siRNA will also rule out the involvement of other possible isoforms of 15	  
TG that might be present.  16	  
 17	  
Removal of AC in vivo is preceded by MØ migration to sites of cell death30. Since 18	  
TG2 cell surface activity has also been reported to be important in cell migration12, 43 19	  
we investigated the ability of TG2 inhibitors to modulate MØ migration towards AC 20	  
using a horizontal migration chamber. We demonstrate that inhibition of TG2 21	  
reduces both the velocity and distance migrated by MØ in response to AC and 22	  
results in a complete loss of directionality. These data suggest that TG2 is involved 23	  
in MØ migration. As syndecan-4 is known to be a key signalling receptor determining 24	  
directional migration44, loss of TG2 which is known to be a strong binding partner 25	  
would have resulted in loss of directional migration. However, it is unclear if this 26	  
effect is mediated through reduced cell adhesion or reduced detection of ‘find me’ 27	  
signals released from apoptotic cells and this requires further study.  28	  
 29	  
In light of the importance of cell surface TG2 in our studies, we addressed the 30	  
mechanism by which TG2 may arrive at the MØ surface.  Syndecan-4, a HSPG, has 31	  
been shown to act, in non-MØ, as a receptor for TG2 via its HS chains where it can 32	  
mediate TG2 translocation to the cell surface and ECM5, 11. Here we demonstrate 33	  
	   34	  
syndecan-4 expression in all our THP-1 cell-derived models, irrespective of their 1	  
TG2 expression. Through co-immunoprecipitation studies we demonstrated 2	  
syndecan-4 interacts with TG2 (where expressed), consistent with earlier studies5, 6, 3	  
8, 10. Loss of syndecan-4 or cell surface HS resulted in significant loss of cell surface 4	  
TG2 expression and activity, affecting MØ-AC interaction. Interestingly, whilst two 5	  
different siRNA constructs for syndecan-4 resulted in reduced syndecan-4 6	  
expression, only the most robust blockade of syndecan-4 impacted on surface TG2 7	  
expression and activity, possibly suggesting that a threshold of syndecan 4 is 8	  
required on the cell surface for TG2 function. Taken together with the inhibitory effect 9	  
of the P1 peptide, which mimics the syndecan-4 binding domain within the TG2 10	  
molecule8, and which can be rescued through the addition of exogenous TG2, these 11	  
data support the notion that cell surface TG2, in association with HS of syndecan-4 12	  
mediates MØ-AC interaction. Sequential knockdown of syndecan-4 expression and 13	  
inhibition of TG2 activity together showed no further reduction in AC clearance 14	  
suggesting TG2 exerts most, if not all of its cell surface effects on AC clearance 15	  
through its association with syndecan-4.  16	  
 17	  
Interaction of cell surface adhesion molecules either with ECM components or 18	  
neighbouring cells are known to influence cell behaviour including phagocytosis. 19	  
CD44, a principal surface receptor for the ECM molecule hyaluronan (a well-known 20	  
cell-cell and cell-matrix interaction mediator), is known for recruiting monocytes to 21	  
sites of inflammation45 and is implicated in AC clearance46. Furthermore CD44, an 22	  
HSPG, is a known phagocytic receptor38 that, when cross-linked experimentally by 23	  
antibody augments AC clearance by an, as yet, incompletely defined mechanism20. 24	  
In light of these pieces of information, we hypothesised that TG2 might modulate AC 25	  
clearance by mediating CD44 cross-linking to promote AC clearance. Co-26	  
immunoprecipitation studies revealed an interaction between TG2 and CD44 but this 27	  
may be a direct or indirect interaction.  CD44 was also detected at the MØ cell 28	  
surface and was detected in TG2-expressing MØ (THP-derived or HMDMØ) as two 29	  
distinct molecular weight bands. CD44 exists in variant isoforms as a result of 30	  
alternative splicing or variable N- and O- linked glycosylation36, 47, 48. CD44s is the 31	  
most prevalent form (40kDa) and with extensive post-translation glycosylation can 32	  
increase in mass (80kDa)49, 50. Notably, TG2 inhibition with a cell-impermeable 33	  
inhibitor resulted in reduced high molecular CD44 and an increased intensity of low 34	  
	   35	  
molecular weight CD44. Biotin cadaverine incorporation by cell surface TG2 and 1	  
subsequent pulling down of labelled substrates with Neutr-Avidin and probing for 2	  
CD44 on western blot showed high and low molecular weight CD44 but a loss of 3	  
high molecular weight CD44 was evident upon treatment with TG2 inhibitor R281 4	  
prior to biotin-cadaverine incorporation. This confirms that in situ CD44 is a potential 5	  
substrate of MØ-cell surface TG2. These data suggest that CD44 is a substrate of 6	  
TG2 and can be cross-linked by the enzyme via a mechanism requiring its binding to 7	  
cell surface HS.  This may provide a physiological equivalent of antibody cross-8	  
linking to augment AC clearance by MØ20. Taken together, our data support the 9	  
hypothesis that TG2 exerts its effect on AC clearance through the cell surface 10	  
association with its high affinity binding partner syndecan-4 and that this may be due, 11	  
at least in part, through CD44 cross-linking. However, further work is required to 12	  
assess the details of this interaction and the subsequent downstream signalling that 13	  
results.  14	  
MØ-CD44 ligation mediated augmented AC intake is evident in both in vitro and in 15	  
vivo20, 51 conditions.  Cuff et al. demonstrated that CD44 promotes MØ recruitment to 16	  
atherosclerotic lesions (sites of extensive cell death)52, while MØ from CD44-/- mice 17	  
showed delayed migration into areas of inflammation53 and a defective clearance of 18	  
AC46. Interestingly, our MØ migration studies revealed reduced migration and 19	  
directionality following TG2 inhibition. Taken together these suggest TG2, syndecan-20	  
4 and CD44 may work together to mediate migration to and clearance of AC. Such a 21	  
mechanism for TG2 involvement in cell migration is not without precedent, since TG2 22	  
binding to syndecan-4 has also been implicated in the crosslinking of cell surface 23	  
S100A4 resulting in the increased motility of mammary cancer cells12.  24	  
Overall, it seems likely that the binding of TG2 to cell surface heparan sulphates 25	  
(e.g. on syndecan 4, CD44 and potentially other molecules), which are required for 26	  
its translocation to the MØ cell surface, may provide the platform for TG2’s 27	  
interaction with a range of other cell surface molecules to mediate a range of TG2-28	  
mediated functions.  Such functions may include those where the enzyme is brought 29	  
into contact with substrates (such as CD44, S100A4 or the large latent TGF-beta 30	  
binding proteins) and also other high-affinity binding proteins such as fibronectin and 31	  
integrins (β1 and β3), the latter of which are needed for cell adhesion, migration40 32	  
and phagocytosis19.  Indeed this may help to explain the compensatory increase in 33	  
	   36	  
β3 integrin expression seen macrophages from TG2-/- animals.  To date the 1	  
molecular mechanism by which CD44-augmented phagocytosis occurs remains to 2	  
be elucidated but it has been shown unequivocally to be independent of serum 3	  
opsonins and glucocorticoid-induced Mer-tk/protein S pathway20.  CD44 crosslinking 4	  
has been suggested to stabilise AC-MØ interactions through an ill-defined 5	  
mechanism but the proposal that CD44 is a substrate for TG2 raises the possibility of 6	  
a functional link between CD44 and the established role of TG2 in the development 7	  
of phagocytic portals19. 8	  
In conclusion, we demonstrate that TG2 associates with HS during its translocation 9	  
to the cell surface of human macrophages. At this site, in association with syndecan-10	  
4, its crosslinking activity is central for it to exert its effect on AC removal, at least in 11	  
part, by promoting tethering of AC. However TG2 is also involved in human MØ 12	  
migration to dying cells, raising the possibility that TG2 inhibitors may be used to 13	  
modulate MØ migration for therapeutic gain, in those situations where MØ migration 14	  
to dying cells is not beneficial.  We further reveal a novel TG2-CD44 interaction and 15	  
demonstrate that CD44 is a potential substrate of TG2 and that inhibition of TG2 16	  
activity reduces high molecular weight CD44 complexes. Such complexes may play 17	  
a role in augmenting AC clearance at least in part through CD44 cross-linking.  This 18	  
is entirely compatible with established ability of TG2 to function with MFG-E8 and β3 19	  
integrin to remove AC and mediate its uptake via signalling the recruitment of CrkII-20	  
DOCK180-Rac1 complex and thus activating GTPase Rac121. Further work is now 21	  
needed to assess, in detail, the importance of CD44-TG2 interactions to AC 22	  
clearance and to define the nature of the TG2-mediated high molecular mass 23	  
complexes that result. 24	  
25	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 1	  
 2	  
Supplementary Figure 1: control blots 3	  
(A) Surface biotinylation control:  THP-1/DS cells were surface biotinylated or non-4	  
biotinylated as described in the methods section.  Surface proteins were isolated by 5	  
Neutr-Avidin beads and isolated proteins separated by SDS-PAGE and subject to 6	  
western blot analysis with mouse anti-TG-2.  TG2 was only detected from 7	  
biotinylated cell surfaces. (B) Syndecan 4 (SDC4) immunoprecipitation control:  8	  
Interaction between TG2 and syndecan-4 in THP-1/DS MØ is revealed by co-9	  
immunoprecipitation analysis. THP-1/DS cell lysates were immunoprecipitated either 10	  
by mouse anti-SDC4 mAb or by the IgG1 isotype control antibody (MoPC21). 11	  
Immunoprecipitates were separated by SDS-PAGE and co-precipitation of TG2 12	  
assessed by anti-TG2 western blotting TG2 was only detected following specific IP 13	  
of SDC4. 14	  
15	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 1	  
 2	  
Supplementary Figure 2. TG2 inhibitors reduce AC clearance by MØ.  3	  
(A) THP-1 monocyte (THP-1) cells were stimulated to differentiate to MØ in the 4	  
presence of dihydroxyvitamin D3 (VD3), phorbol ester (PMA) or both (VD3/PMA) for 5	  
48h. Differentiated THP-1 were treated with site-directed irreversible TG2 inhibitors 6	  
R283, Z-DON (cell-permeable), R281 (cell-impermeable) and R294 for 1h and co-7	  
cultured with AC and inhibitors for a further 1h. All four TG2 inhibitors reduced THP-8	  
1/DS and THP-1/PMA interaction with AC whilst a smaller degree of inhibition was 9	  
noted with THP-1/VD3. (B) The dose-dependence of the effect for all three TG2 10	  
inhibitors is shown with three THP-1 MØ models. Data shown is mean ±S.E. for n≥3 11	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independent replicates. Statistical analysis was conducted using ANOVA followed by 1	  
Bonferroni post-test (*P<0.05; *** P<0.001). 2	  
3	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 1	  
 2	  
Supplementary Figure 3. TG2 inhibitors exert no toxic effect on THP-1/MØ.  3	  
(A) THP-1/DS were treated with or without cell-impermeable TG2 inhibitor R281 at 4	  
500µM final concentration for 1hr. Following washing, cells were fixed with 1% w/v 5	  
formaldehyde, stained with DAPI and imaged using fluorescence microscopy. (B) 6	  
THP-1-derived MØ cells were treated with TG2 inhibitors (R281, R294, R283 or Z-7	  
DON) for 1h and subsequently incubated with XTT reagent for 4h, as per the 8	  
manufacturer’s instructions. Colour development, a measure of cell viability, was 9	  
read at 490nm. MØ treated with H2O2 was used as positive control. Data shown is 10	  
mean ±S.E. for n≥3 independent replicates. Statistical analysis was conducted using 11	  
ANOVA followed by Bonferroni post-test (*** P<0.001). 12	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 1	  
 2	  
Supplementary Figure 4. TG2 expression in Mutu B cells.  3	  
Mutu B cells (viable, UV-induced apoptotic cells or apoptotic cell-derived 4	  
microparticles ‘MP’) were prepared for western blot analysis. The anti-TG2 5	  
immunoblot is shown and reveals no detectable TG2 expression in viable B cells, 6	  
apoptotic B cells, or apoptotic B cell-derived microparticles. Pure TG2 (TG2 Std; 7	  
gplTG) is included as a positive control.  Stripped membranes were re-probed with 8	  
anti-β-actin antibody to confirm equal loading.  9	  
10	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 1	  
 2	  
Supplementary Figure 5. TG2 inhibitors reduce cell surface TG2 activity in 3	  
HMDMØ. 4	  
Cell surface TG activity of primary human monocyte-derived MØ (HMDMØ) was 5	  
tested, via biotin-cadaverine incorporation into fibronectin as described in the 6	  
Methods section, in the presence of the indicated TG2 inhibitors. Cell surface TG 7	  
activity is reduced in the presence of irreversible and amine competitive TG2 8	  
inhibitors. Addition of 100ng exogenous TG2 (exo-TG2) in the presence of 10mM 9	  
Ca2+ can rescue the inhibition. The positive control was guinea pig liver TG. The 10	  
negative control was 10mM EDTA to chelate Ca2+ and inactivate TG2. Data shown is 11	  
mean ±S.E. for n≥3 independent replicates. Statistical analysis was conducted using 12	  
ANOVA followed by Bonferroni post-test (*** P<0.001). 13	  
14	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 1	  
Supplementary figure 6. 2	  
(A) Western blot analysis revealing syndecan-4 expression in MØ (THP-1/DS) 3	  
following transfection, as described in the methods, with human syndecan-4-specific 4	  
siRNA constructs and a non-specific siRNA control (NS). Stripped membranes were 5	  
re-probed with mouse anti-β-actin antibody to ensure equal loading. A representative 6	  
blot is shown along with densitometric analysis of SDC4 expression (relative to the 7	  
loading control) from 3 independent replicate knockdown experiments. (B) MØ (THP-8	  
1/DS) cells transfected with TG2-specific siRNA and a non-specific siRNA control 9	  
(NS) to knockdown TG2 were analysed by western blotting for syndecan-4 10	  
expression. Stripped membranes were re-probed with mouse anti-β-actin antibody to 11	  
ensure equal loading (C) MØ (THP-1/DS) were treated with the P1 peptide or its 12	  
scrambled counterpart (P1s) for 1h and co-cultured with AC and inhibitor for a further 13	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1h. Dose-dependent effects of P1 peptide and P1 scrambled (P1s) control peptide 1	  
on MØ-AC interaction are shown. Data shown is mean ±S.E. for n≥3 independent 2	  
replicates. Statistical analysis was conducted using ANOVA followed by Bonferroni 3	  
post-test (*** P<0.001). 4	  
 5	  
Supplementary figure 7. 6	  
(A) Western blot analysis revealing CD44 expression (detected with mouse anto-7	  
CD44) in MØ (THP-1/DS) following transfection with a panel of human CD44-specific 8	  
siRNA constructs or a non-specific siRNA control (NS siRNA). Stripped membranes 9	  
were re-probed with mouse anti-β-actin antibody to ensure equal loading. (B) MØ 10	  
(THP-1/DS) cells transfected with CD44-specific siRNA (construct #9) to knockdown 11	  
CD44, were analysed by western blotting for cell surface TG2 expression.  A 12	  
representative blot is shown along with the relative densitometric values of the band 13	  
intensities from independent replicates. Data shown are mean ±S.E. for n≥3 14	  
independent replicates. Statistical analysis was conducted using ANOVA followed by 15	  
Bonferroni post-test (NS: Not significant). 16	  
 17	  
18	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TG2 (CUB 7402) Mouse Monoclonal Neomarks, Pierce, UK 
TG2 (TG100) Mouse Monoclonal Neomarks, Pierce, UK 
TG2 Rabbit Polyclonal Neomarks, Pierce, UK 
Isotype control IgG1/κ 
(MOPC21) 
Mouse Monoclonal Sigma-Aldrich, UK 
Syndecan-4 Mouse Monoclonal Santa Cruz 
Biotechnology, UK 
Syndecan-4 Rabbit Polyclonal Invitrogen, UK 
CD44 Mouse Monoclonal Cell Signalling, UK 
α-Tubulin Mouse Monoclonal Sigma-Aldrich, UK 
β-Actin Rabbit Polyclonal Abcam, UK 
 
Secondary Antibodies 
 Host Species Company 
Goat anti-mouse FITC Sigma-Aldrich, UK 
Goat anti-mouse PE Sigma-Aldrich, UK 
Goat anti-mouse HRP Sigma-Aldrich, UK 
Goat anti-rabbit FITC Sigma-Aldrich, UK 
Goat anti-rabbit PE Sigma-Aldrich, UK 
Goat anti-rabbit HRP Sigma-Aldrich, UK 
 3	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